Study details
Enrolling now
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
Axsome Therapeutics, Inc.
NCT IDNCT07398417ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Ages
18+
Locations
16 sites in AR, CA, CT +10
About this study
This Phase 3 study is focused on people with fibromyalgia.
Based on ClinicalTrials.gov records.
PhasePhase 3
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low4%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Body systems
Musculoskeletal